

Prognostic roles of MAGE family members in breast cancer based on KM-Plotter Data

BINGHAN JIA, XIAOLING ZHAO, YAO WANG, JINLONG WANG, YINGYING WANG and YUEMEI YANG

Department of R&D Technology Center, Beijing Zhicheng Biomedical Technology Co., Ltd., Beijing 100730, P.R. China

Received November 15, 2018; Accepted June 19, 2019

DOI: 10.3892/ol.2019.10722

Abstract. Breast cancer is the second leading cause of cancer-associated mortality among women worldwide, and the prevalence and mortality rates associated with this disease are high in Western countries. The melanoma-associated antigen (MAGE) family proteins are well-known tumor-specific antigens; this family includes >60 proteins that serve an important part in cell cycle withdrawal, neuronal differentiation and apoptosis. The aim of the present study was to identify a biomarker within the MAGE family that is specific for breast cancer. In the present study, the prognostic role of MAGE mRNA expression was investigated in patients with breast cancer using the Kaplan-Meier plotter database. The prognostic value of MAGE members in the different intrinsic subtypes of breast cancer was further investigated, as well as the clinicopathological features of the disease. The results of the present study indicated that patients with breast cancer that had high mRNA expression levels of MAGEA5, MAGEA8, MAGEB4 and MAGEB6 had an improved relapse-free survival, whereas those with high mRNA expression levels of MAGEB18 and MAGED4 did not. These results suggested that MAGEA5, MAGEA8, MAGEB4 and MAGEB6 may have roles as tumor suppressors in the occurrence and development of breast cancer, whereas MAGEB18 and MAGED4 may possess carcinogenic potential. MAGED2, MAGED3 and MAGEF1 had different effects depending on the type of breast cancer. In particular, high MAGEC3 mRNA expression was associated with worse RFS in lymph node-positive

breast cancer, but with improved RFS in lymph node-negative breast cancer. In patients with wild-type TP53 and patients with different pathological grades of breast cancer, MAGEE2, MAGEH1 and MAGEI2 were more worthy of attention as potential prognostic factors. The results of the present study may help to elucidate the role of MAGE family members in the development of breast cancer, and may promote further research that identifies MAGE-targeting reagents for the treatment of breast cancer.

Introduction

Breast cancer is the second leading cause of cancer-associated mortality among women worldwide (1). According to one published report, there were >240,000 new cases of breast cancer reported in the United States in 2017, of which >40,000 were expected to succumb to the disease (2). Distant metastasis and chemoresistance are leading causes of patient mortality and treatment failure (3). Despite advances in the screening, diagnosis and treatment options for breast cancer, the incidence and mortality of the disease are still increasing (4). Tumor recurrence and metastatic relapse remain the major contributing factors to the high mortality rates (5). Therefore, there is still an urgent need to investigate novel targets and/or biomarkers that can be used to predict or treat patients with breast cancer.

Melanoma-associated antigen (MAGE) family members are cancer/testis antigens that are expressed in germline cells, trophoblasts and various types of human cancer, including melanoma, lung cancer, breast cancer, oral squamous cell carcinoma, esophageal carcinoma, urothelial malignancies and hematopoietic malignancies (6-11). At present, >60 proteins in this family have been identified and subdivided into two categories on the basis of the location and expression patterns of the protein. The type I MAGE genes are restricted to clusters on the X-chromosome, and include MAGE-A, -B and -C. Their aberrant expression levels occur in numerous types of cancer and they serve as tumor-specific antigens (11,12). Unlike the type I genes, type II MAGE genes are not limited to chromosome clustering and include MAGE-D, -E, -F, -G, -H, -I, -J, -K, -L and necdin subfamilies (11,12). They serve an important role in cell cycle withdrawal, neuronal differentiation and apoptosis (13).

It has been reported that MAGEA1 can inhibit the proliferation and migration of MCF-7 and MDA-MB-231 breast

Correspondence to: Dr Yuemei Yang, Department of R&D Technology Center, Beijing Zhicheng Biomedical Technology Co., Ltd., 18 JianGuo Road, Beijing 100730, P.R. China
E-mail: yyme0408@163.com

Abbreviations: MAGE, melanoma-associated antigen; GEO, Gene Expression Omnibus; RFS, relapse-free survival; OS, overall survival; DMFS, distant metastasis-free survival; PPS, post-progression survival; HR hazard ratio; CI, confidence interval

Key words: breast cancer, melanoma-associated antigen gene family, intrinsic subtypes of breast cancer, clinicopathological features of breast cancer

cancer cell lines (14). In addition, MAGEA1-A3 and A12 have been investigated in the early detection of breast cancer (15). Ayyoub *et al* (16) reported that MAGEA3 and MAGEA6 expression in primary breast cancer is associated with hormone receptor-negative status, high histological grade and poor survival. Cabezón *et al* (17) indicated that MAGEA3 and MAGEA4 may be associated with risk and the clinicopathological parameters of breast cancer (17,18). In breast cancer, MAGEA9-A11 have been identified as being associated with poor prognosis (19-23). Sypniewska *et al* (24,25) demonstrated that MAGEB1-B3 DNA vaccines are useful for breast cancer therapy in a mouse breast tumor model. Hou *et al* (26) reported that MAGEC1 and MAGEC2 may be potential targets for tumor immunotherapy, and demonstrated that MAGEC1 and MAGEC2 expression is associated with advanced stages of breast cancer and poor patient outcome. Du *et al* (27) demonstrated that MAGED1 inhibits the proliferation, migration and invasion of human breast cancer cells. However, the prognostic roles of each individual MAGE, particularly at the mRNA level in breast cancer, remain unknown.

The Kaplan-Meier plotter (KM-Plotter) database (<http://kmplot.com/analysis/>) is generated gene expression data and survival information of 1,809 patients downloading from Gene Expression Omnibus (GEO) (28). This database has been widely used to analyze the clinical impact of individual genes on relapse-free survival (RFS), distant metastasis-free survival (DMFS), overall survival (OS) and post-progression survival (PPS) for different types of cancer. In the present study, the prognostic role of the mRNA expression of each individual member of the MAGE family in breast cancer was assessed using the Kaplan-Meier plotter database.

Materials and methods

Data collection. The KM-Plotter database contains data regarding the survival of 3,955 patients with breast cancer (RFS data) (28). The association between the mRNA expression levels of individual MAGE family member genes and RFS was analyzed using an online KM-Plotter database using the gene expression data and the survival information of patients with breast cancer downloaded from the GEO (<https://www.ncbi.nlm.nih.gov/pubmed/20020197>) (28). Cohorts of patients were split by median expression values through auto select best cut-off. A collection of clinical data, including estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2) status, lymph node status, tumor pathological grade (29), intrinsic subtype and TP53 status were collected.

Different subtypes of breast cancer analysis by KM-Plotter. Briefly, 29 individual members of the MAGE family were entered into the database (kmplot.com/analysis/index.php?p=service&start=1) to obtain Kaplan-Meier survival plots. Of the 29 individual members of the MAGE family, 14 were selected to focus on: MAGEA5, -A8, -B4, -B6, -B18, -C3, -D2, -D3, -D4, -E1, -E2, -F1, -H1 and -L2, which, to the best of our knowledge, have not been reported in the literature by searching PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/>), Elsevier ScienceDirect (<http://www.sciencedirect.com/>) and Google Scholar (<https://scholar.google.com/>). Subsequently,

they were used to analyze the different subtypes of breast cancer by KM-Plotter.

Clinicopathological features of breast cancer by KM-Plotter.

In addition, in order to further examine the clinicopathological survival condition 14 genes were studied. The clinicopathological features of breast cancer through the KM-Plotter, including the lymph node status, tumor grade, TP53 status and Pietenpol subtype (30) were examined.

Statistical analysis. The Kaplan-Meier survival plots with number at risk, hazard ratio (HR), 95% confidence intervals (CI) and log-rank P-values were obtained using the Kaplan-Meier plotter website. According to American Psychological Association (APA) formatting for P-values, $P < 0.05$ was used indicate a statistically significant difference.

Results

Prognostic values of MAGE members in all patients with breast cancer. The prognostic values of the mRNA expression levels of 29 MAGE family members in patients with breast cancer were obtained from the Kaplan-Meier plotter website. Among these 29 MAGE members, 28 were significantly associated with the prognosis of all types of breast cancer (Fig. 1A). High mRNA expression levels of MAGEA1 (HR, 0.81; 95% CI, 0.71-0.91; $P=0.0005$), MAGEA4 (HR, 0.84; 95% CI, 0.75-0.93; $P=0.0012$), MAGEA5 (HR, 0.79; 95% CI, 0.71-0.88; $P=2.5 \times 10^{-5}$), MAGEA6 (HR, 0.87; 95% CI, 0.77-0.98; $P=0.0200$), MAGEA8 (HR, 0.71; 95% CI, 0.63-0.79; $P=4.0 \times 10^{-10}$), MAGEA9 (HR, 0.82; 95% CI, 0.72-0.93; $P=0.0016$), MAGEA10 (HR, 0.63; 95% CI, 0.56-0.71; $P=3.7 \times 10^{-15}$), MAGEA11 (HR, 0.80; 95% CI, 0.71-0.90; $P=0.0003$), MAGEA12 (HR, 0.79; 95% CI, 0.70-0.89; $P=8.7 \times 10^{-5}$) (Fig. 1B-1/4/5/6/8/9/10/11); MAGEB1 (HR, 0.82; 95% CI, 0.74-0.92; $P=0.0005$), MAGEB2 (HR, 0.68; 95% CI, 0.61-0.76; $P=6.8 \times 10^{-12}$), MAGEB3 (HR, 0.83; 95% CI, 0.74-0.93; $P=0.0017$), MAGEB4 (HR, 0.84; 95% CI, 0.73-0.95; $P=0.0058$), MAGEB6 (HR, 0.78; 95% CI, 0.65-0.92; $P=0.0031$), MAGEC1 (HR, 0.72; 95% CI, 0.64-0.82; $P=2.2 \times 10^{-7}$), MAGEC2 (HR, 0.67; 95% CI, 0.60-0.75; $P=6.7 \times 10^{-13}$), MAGEC3 (HR, 0.76; 95% CI, 0.68-0.86; $P=7.5 \times 10^{-6}$), MAGED2 (HR, 0.78; 95% CI, 0.69-0.87; $P=3.1 \times 10^{-5}$), MAGED3 (HR, 0.82; 95% CI, 0.74-0.92; $P=0.0009$), MAGEE1 (HR, 0.73; 95% CI, 0.62-0.86; $P=8.7 \times 10^{-5}$), MAGEF1 (HR, 0.76; 95% CI, 0.67-0.85; $P=4.2 \times 10^{-6}$) and MAGEL2 (HR, 0.77; 95% CI, 0.68-0.87; $P=4.3 \times 10^{-5}$) (Fig. 1C-1/2/3/4/5/7/8/9/11/12/14/16/18) were observed to be significantly associated with better prognosis. High mRNA expression levels of MAGED1 (HR, 1.49; 95% CI, 1.33-1.68; $P=8.1 \times 10^{-12}$), MAGED4 (HR, 1.26; 95% CI, 1.13-1.42; $P=6.6 \times 10^{-5}$) and MAGEH1 (HR, 1.29; 95% CI, 1.15-1.45; $P=1.7 \times 10^{-5}$) (Fig. 1C-10/13/17) were significantly associated with worse RFS, whereas the expression levels of MAGEA2 (HR, 1.11; 95% CI, 0.99-1.23; $P=0.0700$) (Fig. 1B-2) were not associated with RFS. High mRNA expression levels of MAGEA3 (HR, 0.87; 95% CI, 0.77-0.98; $P=0.0270$; Fig. 1B-3) and MAGEE2 (HR, 0.81; 95% CI, 0.67-0.98; $P=0.0290$; Fig. 1C-15) were significantly associated with improved prognosis, and low mRNA expression of MAGEB18 (HR, 1.17;




Figure 1. Prognostic value of the mRNA expression levels of the MAGE family members using the Kaplan-Meier plotter database. (A) Prognostic HRs of individual MAGE family members in all types of breast cancer. Red indicates HR≥1, green indicates HR<1 and black indicates HR (0.99-1.23). (B) Kaplan-Meier survival curves of the mRNA expression levels of MAGE family members. 1, MAGEA1; 2, MAGEA2; 3, MAGEA3; 4, MAGEA4; 5, MAGEA5; 6, MAGEA6; 7, MAGEA8; 8, MAGEA9; 9, MAGEA10; 10, MAGEA11; and-11, MAGEA12 for all breast cancer patients (n=3,955). All BC, all breast cancer; HR, hazard ratio; MAGE, melanoma-associated antigen.




Figure 1. Continued. (C) Kaplan-Meier survival curves of the mRNA expression levels of MAGE family members. 1, MAGEB1; 2, MAGEB2; 3, MAGEB3; 4, MAGEB4; 5, MAGEB6; 6, MAGEB18; 7, MAGEC1; 8, MAGEC2; 9, MAGEC3; 10, MAGED1; 11, MAGED2; 12, MAGED3; 13, MAGED4; 14, MAGEE1; 15, MAGEE2; 16, MAGEF1; 17, MAGEH1; and 18, MAGEL2 for all breast cancer patients (n=3,955). All BC, all breast cancer; HR, hazard ratio; MAGE, melanoma-associated antigen.

95% CI, 1.00-1.36; P=0.0490; Fig. 1C-6) was significantly associated with better prognosis.

Prognostic value of 14 MAGE members in different subtypes of breast cancer. The prognostic values of 14 MAGE members




Figure 2. Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEA5, (B) MAGEA8, (C) MAGEB4, (D) MAGEB6, (E) MAGEC3, (F) MAGED2, (G) MAGEE2, (H) MAGEF1 and (I) MAGEH1 for patients with basal-like breast cancer subtypes (n=879). HR, hazard ratio; MAGE, melanoma-associated antigen.

within the different intrinsic subtypes of breast cancer were determined, including all basal-like, luminal A, luminal B and HER2⁺. As presented in Fig. 2, high mRNA expression levels of MAGEA8 (HR, 0.59; 95% CI, 0.45-0.77; P=7.9×10⁻⁵; Fig. 2B), MAGEB4 (HR, 0.61; 95% CI, 0.46-0.82; P=0.0009; Fig. 2C) and MAGEB6 (HR, 0.61; 95% CI, 0.43-0.85; P=0.0035; Fig. 2D) were significantly associated with improved RFS in patients with the basal-like breast cancer subtype. High mRNA expression levels of MAGEA5 (HR, 0.75; 95% CI, 0.58-0.98; P=0.0320; Fig. 2A), MAGEC3 (HR, 0.70; 95% CI, 0.52-0.94; P=0.0180; Fig. 2E) MAGEE2 (HR, 0.64; 95% CI, 0.43-0.94; P=0.0230; Fig. 2G) and MAGEF1 (HR, 0.73; 95% CI, 0.56-0.95; P=0.0170; Fig. 2H) were significantly associated with improved RFS in patients with basal-like breast cancer

subtype. However, high mRNA expression levels of MAGEH1 (HR, 1.51; 95% CI, 1.17-1.96; P=0.0016; Fig. 2I) were significantly associated with worse RFS in patients with the basal-like breast cancer subtype and high mRNA expression levels of MAGED2 (HR, 1.34; 95% CI, 1.02-1.74; P=0.0330; Fig. 2F) was significantly associated with improved RFS in patients with basal-like breast cancer subtype. The survival curves for the remaining members of the MAGE family in patients with basal-like breast cancer subtype were investigated, but they were not significantly associated with prognosis (Fig. S1).

In patients with luminal A breast cancer, high mRNA expression levels of MAGEA5 (HR, 0.71; 95% CI, 0.60-0.84; P=8.9×10⁻⁵; Fig. 3A), MAGEA8 (HR, 0.69; 95% CI, 0.58-0.83; P=6.6×10⁻⁵; Fig. 3B), MAGEC3 (HR, 0.71; 95% CI, 0.59-0.85,




Figure 3. Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEA5, (B) MAGEA8, (C) MAGEB4, (D) MAGEC3, (E) MAGED3, (F) MAGEE1, (G) MAGEF1, (H) MAGEH1 and (I) MAGEL2 for patients with the luminal A breast cancer subtype (n=2,504). HR, hazard ratio; MAGE, melanoma-associated antigen.

P=0.0003; Fig. 3D); MAGED3 (HR, 0.71; 95% CI, 0.58-0.88; P=0.0016; Fig. 3E), MAGEF1 (HR, 0.74; 95% CI, 0.61-0.88; P=0.0009; Fig. 3G) and MAGEL2 (HR, 0.73; 95% CI, 0.60-0.88; P=0.0013; Fig. 3I) were significantly associated with improved RFS. In contrast, high mRNA expression levels of MAGEH1 (HR, 1.20; 95% CI, 1.01-1.43; P=0.0350; Fig. 3H) were significantly associated with worse RFS. High expression levels of MAGEB4 (HR, 0.84; 95% CI, 0.70-1.00; P=0.0470; Fig. 3C) and MAGEE1 (HR, 0.74; 95% CI, 0.57-0.96; P=0.0250; Fig. 3F) were significantly associated with improved RFS. The remaining MAGE family members were not significantly associated with the prognosis of luminal A breast cancer (Fig. S2).

In luminal B breast cancer, high mRNA expression levels of MAGEA5 (HR, 0.70; 95% CI, 0.58-0.85; P=0.0002; Fig. 4A), MAGEA8 (HR, 0.68; 95% CI, 0.56-0.83; P=9.6×10⁻⁵; Fig. 4B), MAGEB4 (HR, 0.72; 95% CI, 0.59-0.89; P=0.0020; Fig. 4C), MAGEC3 (HR, 0.73; 95% CI, 0.60-0.88; P=0.0011; Fig. 4E), MAGED3 (HR, 0.78; 95% CI, 0.64-0.94; P=0.0110; Fig. 4F), MAGEE1 (HR, 0.68; 95% CI, 0.49-0.93; P=0.0016; Fig. 4G) was significantly associated with improved RFS. High mRNA expression levels of MAGEL2 (HR, 0.80; 95% CI, 0.66-0.97; P=0.0210; Fig. 4I) was significantly associated with improved RFS. However, high mRNA expression levels of MAGEH1 (HR, 1.55; 95% CI, 1.26-1.90; P=2.4×10⁻⁵; Fig. 4H) was significantly associated with worse RFS and high mRNA expression




Figure 4. Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEA5, (B) MAGEA8, (C) MAGEB4, (D) MAGEB18, (E) MAGEC3, (F) MAGED3, (G) MAGEE1, (H) MAGEH1 and (I) MAGEL2 for patients with the luminal B breast cancer subtype (n=1,425). HR, hazard ratio; MAGE, melanoma-associated antigen.

levels of MAGEB18 (HR, 1.44; 95% CI, 1.06-1.97; P=0.0200; Fig. 4D) was significantly associated with worse RFS. The remaining MAGE members were not significantly associated with the prognosis of luminal B breast cancer (Fig. S3).

In HER2⁺ breast cancer, high mRNA expression levels of MAGEA8 (HR, 0.67; 95% CI, 0.46-0.99; P=0.0410; Fig. 5A) and MAGEC3 (HR, 0.62; 95% CI, 0.42-0.90; P=0.0120; Fig. 5B) were significantly associated with improved RFS. However, high mRNA expression levels of MAGE2 (HR, 1.82; 95% CI, 1.24-2.68; P=0.0020; Fig. 5C) and MAGEH1 (HR, 1.79; 95% CI, 1.21-2.64; P=0.0032; Fig. 5D) were significantly associated with worse RFS. The remaining MAGE family members were not significantly associated with the RFS of HER2⁺ breast cancer (Fig. S4).

Prognostic values of 14 MAGE members in breast cancer according to clinicopathological features. The present study also investigated the association between the MAGE family members and patients' clinicopathological features. As presented in Table I, high mRNA expression levels of MAGEF1 (HR, 0.75; 95% CI, 0.61-0.93; P=0.0094) were significantly associated with improved RFS in lymph node-positive breast cancer. In contrast, high mRNA expression levels of MAGEF1 (HR, 1.26; 95% CI, 1.07-1.50; P=0.0063) were significantly associated with worse RFS in lymph node-negative breast cancer. High mRNA expression levels of MAGED2 were significantly associated with improved RFS in lymph node-positive breast cancer (HR, 0.79; 95% CI, 0.65-0.96; P=0.0200) and lymph node-negative breast cancer (HR, 0.82;




Figure 5. Kaplan-Meier survival curves of the mRNA expression levels of (A) MAGEA8, (B) MAGEC3, (C) MAGED2 and (D) MAGEH1 for patients with the HER2⁺ breast cancer subtype (n=335). HER2, human epidermal growth factor receptor 2; HR, hazard ratio; MAGE, melanoma-associated antigen.

95% CI, 0.68-0.99; P=0.0400) breast cancer. MAGED4 expression levels were significantly associated with worse prognosis in lymph node-positive breast cancer (HR, 1.24; 95% CI, 1.02-1.51; P=0.0290) and significantly associated with worse prognosis in lymph node-negative breast cancer (HR, 1.27; 95% CI, 1.07-1.51; P=0.0062). High mRNA expression levels of MAGED3 (HR, 0.81; 95% CI, 0.67-0.99; P=0.0390) were significantly associated with improved RFS in lymph node-positive breast cancer. High mRNA expression levels of MAGEA5 (HR, 1.24; 95% CI, 1.00-1.53; P=0.0447), MAGED4 (HR, 1.24; 95% CI, 1.02-1.51; P=0.0290) and MAGEH1 (HR, 1.30; 95% CI, 1.04-1.62; P=0.0185) were significantly associated with worse RFS in lymph node-positive breast cancer. However, high mRNA expression levels of MAGEB6 (HR, 0.55; 95% CI, 0.33-0.91; P=0.0188), MAGEE2 (HR, 0.57; 95% CI, 0.33-0.98; P=0.0376) and MAGEL2 (HR, 0.83; 95% CI, 0.69-1.00; P=0.0464) were significantly associated with improved RFS in lymph node-negative breast cancer. The remaining MAGE family members were not significantly associated with the RFS of lymph node positive and negative breast cancer.

As presented in Table II, high mRNA expression levels of MAGEB6 (HR, 0.29; 95% CI, 0.10-0.83; P=0.0136), MAGEE1 (HR, 0.35; 95% CI, 0.12-1.02; P=0.0435) and MAGEH1 (HR, 0.52; 95% CI, 0.30-0.88; P=0.0140) in grade I breast cancer; MAGEA8 (HR, 0.74; 95% CI, 0.57-0.96; P=0.0248) and MAGEC3 (HR, 0.74; 95% CI, 0.57-0.96; P=0.0210) in grade II breast cancer; and MAGEA8 (HR, 0.78; 95% CI,

0.61-0.99; P=0.0373) in grade III breast cancer were significantly associated with improved RFS. High expression levels of MAGEF1 (HR, 0.70; 95% CI, 0.54-0.90; P=0.0057) and MAGEH1 (HR, 0.63; 95% CI, 0.47-0.85; P=0.0020) in grade II breast cancer; and MAGEB4 (HR, 0.72; 95% CI, 0.58-0.90; P=0.0041) and MAGEB6 (HR, 0.62; 95% CI, 0.46-0.85; P=0.0029) in grade III breast cancer were significantly associated with improved RFS.

High mRNA expression levels of MAGEB4 (HR, 1.91; 95% CI, 1.06-3.43; P=0.0288) and MAGEB18 (HR, 3.46; 95% CI, 1.20-9.98; P=0.0142) in grade I breast cancer were significantly associated with worse RFS; high mRNA expression levels of MAGED4 (HR, 1.52; 95% CI, 1.18-1.95; P=0.0009) in grade II breast cancer; and MAGED2 (HR, 1.39; 95% CI, 1.11-1.73; P=0.0042), MAGED3 (HR, 1.35; 95% CI, 1.07-1.69; P=0.0101), MAGEE1 (HR, 1.53; 95% CI, 1.12-2.08; P=0.0075) in grade III breast cancer were significantly associated with worse RFS; high mRNA expression levels of MAGEL2 (HR, 1.25; 95% CI, 1.01-1.56; P=0.0420) in grade III were significantly associated with worse RFS. The remaining MAGE family members were not associated with the RFS of different grade breast cancer.

As shown in Table III, high mRNA expression levels of MAGEB4 (HR, 0.53; 95% CI, 0.31-0.88; P=0.0136) and MAGED3 (HR, 0.59; 95% CI, 0.37-0.95; P=0.0280) were significantly associated with improved RFS in patients with TP53-mutated breast cancer, whereas high mRNA expression levels of MAGEL2 (HR, 0.58; 95% CI, 0.34-0.99; P=0.0430)

Table I. Associations between the different MAGE family members and positive or negative lymph node status of patients with breast cancer.

MAGE family member	Affymetrix ID	Lymph node status	HR	95% CI	P-value
MAGEA5	214642_x_at	Positive	1.24 ^b	1.00-1.53 ^b	0.0447 ^b
		Negative	0.90	0.76-1.06	0.2129
MAGEA8	210274_at	Positive	1.22	0.99-1.52	0.0646
		Negative	0.85	0.71-1.03	0.0946
MAGEB4	207580_at	Positive	1.18	0.95-1.48	0.1385
		Negative	0.87	0.72-1.06	0.1809
MAGEB6	1552858_at	Positive	0.78	0.60-1.00	0.0515
		Negative	0.55 ^a	0.33-0.91 ^a	0.0188 ^a
MAGEB18	1552913_at	Positive	0.84	0.65-1.09	0.1869
		Negative	1.47	0.98-2.21	0.0601
MAGEC3	216592_at	Positive	1.20	0.98-1.48	0.0810
		Negative	0.85	0.71-1.01	0.0640
MAGED2	213627_at	Positive	0.79 ^a	0.65-0.96 ^a	0.0200 ^a
		Negative	0.82 ^a	0.68-0.99 ^a	0.0400 ^a
MAGED3	205028_at	Positive	0.81 ^a	0.67-0.99 ^a	0.0390 ^a
		Negative	1.10	0.93-1.30	0.2800
MAGED4	221261_x_at	Positive	1.24 ^b	1.02-1.51 ^b	0.0290 ^b
		Negative	1.27 ^b	1.07-1.51 ^b	0.0062 ^b
MAGEE1	1556047_s_at	Positive	0.81	0.62-1.04	0.1013
		Negative	0.79	0.54-1.17	0.2400
MAGEE2	1553254_at	Positive	1.23	0.95-1.58	0.1096
		Negative	0.57 ^a	0.33-0.98 ^a	0.0376 ^a
MAGEF1	218176_at	Positive	0.75 ^a	0.61-0.93 ^a	0.0094 ^a
		Negative	1.26 ^b	1.07-1.50 ^b	0.0063 ^b
MAGEH1	218573_at	Positive	1.30 ^b	1.04-1.62 ^b	0.0185 ^b
		Negative	0.91	0.75-1.11	0.3438
MAGEL2	219894_at	Positive	1.08	0.88-1.31	0.4600
		Negative	0.83 ^a	0.69-1.00 ^a	0.0464 ^a

P<0.05 was considered to indicate a statistically significant difference. ^aHigh mRNA expression levels associated with improved RFS; ^bhigh mRNA expression levels associated with worse RFS. Total patients assigned a lymph node status, n=3,718; lymph node-positive patients, n=1,459; lymph node-negative patients, n=2,259, analyzed by ANOVA. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen; RFS, relapse-free survival.

were significantly associated with improved RFS in TP53 wild-type breast cancer. In contrast, high mRNA expression levels of MAGED2 (HR, 2.10; 95% CI, 1.28-3.46; P=0.0028) were significantly associated with worse RFS in TP53-mutated breast cancer. High mRNA expression levels of MAGEB18 (HR, 3.51; 95% CI, 1.50-8.22; P=0.0021) and MAGED4 (HR, 1.82; 95% CI, 1.18-2.83; P=0.0065) were significantly associated with worse RFS in TP53 wild-type breast cancer; and high mRNA expression levels of MAGEE2 (HR, 2.35; 95% CI, 1.01-5.48; P=0.0414), MAGEB6 (HR, 5.08; 95% CI, 1.18-21.89; P=0.0157) were significantly associated with worse RFS in TP53 wild-type breast cancer. Notably, high mRNA expression levels of MAGEF1 were significantly associated with worse RFS in TP53-mutated (HR, 1.68; 95% CI, 1.04-2.71; P=0.0318) and TP53 wild-type (HR, 1.65; 95% CI,

1.06-2.55; P=0.0240) breast cancer. The remaining MAGE family members were not significantly associated with RFS of TP53 mutated and wild-type breast cancer.

As presented in Table IV, high mRNA expression levels of MAGEA8 in the basal-like 1 subtype (HR, 0.50; 95% CI, 0.31-0.83; P=0.0059) and luminal androgen receptor subtype (HR, 0.52; 95% CI, 0.31-0.85; P=0.0076); and MAGEB18 in mesenchymal stem-like breast cancer subtype (HR, 0.19; 95% CI, 0.05-0.66; P=0.0039) were significantly associated with improved RFS. High expression levels of MAGEA5 in the basal-like 1 subtype (HR, 0.60; 95% CI, 0.37-0.96; P=0.0327); MAGEB6 (HR, 0.43; 95% CI, 0.19-0.97; P=0.0356), MAGED2 (HR, 0.46; 95% CI, 0.23-0.95; P=0.0308), MAGEE1 (HR, 0.25; 95% CI, 0.07-0.85; P=0.0160), MAGEF1 (HR 0.33; 95% CI, 0.14-0.81; P=0.0110)

Table II. Association between the MAGE family members and pathological tumor grade of patients with breast cancer.

MAGE family member	Affymetrix ID	Tumor grade	HR	95% CI	P-value
MAGEA5	214642_at	I	0.72	0.43-1.22	0.2269
		II	1.27	0.95-1.68	0.1038
		III	1.12	0.88-1.43	0.3578
MAGEA8	210274_at	I	0.63	0.33-1.22	0.1702
		II	0.74 ^a	0.57-0.96 ^a	0.0248 ^a
		III	0.78 ^a	0.61-0.99 ^a	0.0373 ^a
MAGEB4	207580_at	I	1.91 ^b	1.06-3.43 ^b	0.0288 ^b
		II	0.79	0.60-1.02	0.0732
		III	0.72 ^a	0.58-0.90 ^a	0.0041 ^a
MAGEB6	1552858_at	I	0.29 ^a	0.10-0.83 ^a	0.0136 ^a
		II	1.19	0.72-1.99	0.4982
		III	0.62 ^a	0.46-0.85 ^a	0.0029 ^a
MAGEB18	1552913_at	I	3.46 ^b	1.20-9.98 ^b	0.0142 ^b
		II	1.65	0.93-2.93	0.0840
		III	1.27	0.90-1.78	0.1706
MAGEC3	216592_at	I	1.51	0.80-2.85	0.2000
		II	0.74 ^a	0.57-0.96 ^a	0.0210 ^a
		III	0.89	0.71-1.11	0.2900
MAGED2	213627_at	I	1.47	0.87-2.48	0.1500
		II	0.86	0.67-1.10	0.2200
		III	1.39 ^b	1.11-1.73 ^b	0.0042 ^b
MAGED3	205028_at	I	1.64	0.95-2.83	0.0720
		II	0.79	0.62-1.01	0.0620
		III	1.35 ^b	1.07-1.69 ^b	0.0101 ^b
MAGED4	221261_x_at	I	0.54	0.26-1.10	0.0827
		II	1.52 ^b	1.18-1.95 ^b	0.0009 ^b
		III	1.20	0.97-1.50	0.0946
MAGEE1	1556047_s_at	I	0.35 ^a	0.12-1.02 ^a	0.0435 ^a
		II	0.61	0.35-1.05	0.0730
		III	1.53 ^b	1.12-2.08 ^b	0.0075 ^b
MAGEE2	1553254_at	I	0.56	0.19-1.67	0.2903
		II	1.22	0.73-2.04	0.4500
		III	1.18	0.87-1.61	0.2900
MAGEF1	218176_at	I	0.67	0.36-1.24	0.1993
		II	0.70 ^a	0.54-0.90 ^a	0.0057 ^a
		III	0.85	0.67-1.08	0.1788
MAGEH1	218573_at	I	0.52 ^a	0.30-0.88 ^a	0.0140 ^a
		II	0.63 ^a	0.47-0.85 ^a	0.0020 ^a
		III	1.18	0.94-1.49	0.1600
MAGEL2	219894_at	I	0.71	0.42-1.19	0.1907
		II	0.79	0.62-1.00	0.0513
		III	1.25 ^b	1.01-1.56 ^b	0.0420 ^b

P<0.05 was considered to indicate a statistically significant difference. ^aHigh mRNA expression levels associated with improved RFS; ^bhigh mRNA expression levels associated with worse RFS. Total patients with a pathological tumor grade, n=2,545; patients with tumor grade I, n=378; patients with tumor grade II, n=1,077; patients with tumor grade III, n=1,090 patients. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen; RFS, relapse-free survival.

in the basal-like 2 subtype; MAGEB6 (HR, 0.41; 95% CI, 0.17-0.96; P=0.0333) in the immunomodulatory subtype;

MAGEA8 (HR, 0.60; 95% CI, 0.38-0.95; P=0.0268), MAGEB6 (HR, 0.47; 95% CI, 0.24-0.89; P=0.0181), MAGEL2

Table III. Association between MAGE family members and the TP53 status of patients with breast cancer.

MAGE family member	Affymetrix ID	TP53 status	HR	95% CI	P-value
MAGEA5	214642_at	Mutated	1.38	0.81-2.37	0.2357
		Wild-type	1.39	0.88-2.17	0.1236
MAGEA8	210274_at	Mutated	0.69	0.43-1.12	0.1317
		Wild-type	0.80	0.50-1.27	0.3462
MAGEB4	207580_at	Mutated	0.53 ^a	0.31-0.88 ^a	0.0136 ^a
		Wild-type	0.78	0.51-1.20	0.2634
MAGEB6	1552858_at	Mutated	0.64	0.34-1.18	0.1506
		Wild-type	5.08 ^b	1.18-21.89 ^b	0.0157
MAGEB18	1552913_at	Mutated	0.66	0.35-1.24	0.1931
		Wild-type	3.51 ^b	1.50-8.22 ^b	0.0021 ^b
MAGEC3	216592_at	Mutated	0.75	0.46-1.23	0.2500
		Wild-type	0.85	0.56-1.31	0.4700
MAGED2	213627_at	Mutated	2.10 ^b	1.28-3.46 ^b	0.0028 ^b
		Wild-type	0.80	0.53-1.23	0.3100
MAGED3	205028_at	Mutated	0.59 ^a	0.37-0.95 ^a	0.0280 ^a
		Wild-type	0.74	0.45-1.21	0.2286
MAGED4	221261_x_at	Mutated	0.71	0.44-1.14	0.1513
		Wild-type	1.82 ^b	1.18-2.83 ^b	0.0065 ^b
MAGEE1	1556047_s_at	Mutated	1.76	0.96-3.25	0.0660
		Wild-type	0.48	0.19-1.23	0.1200
MAGEE2	1553254_at	Mutated	0.54	0.25-1.17	0.1138
		Wild-type	2.35 ^b	1.01-5.48 ^b	0.0414 ^b
MAGEF1	218176_at	Mutated	1.68 ^b	1.04-2.71 ^b	0.0318 ^b
		Wild-type	1.65 ^b	1.06-2.55 ^b	0.0240 ^b
MAGEH1	218573_at	Mutated	1.60	0.98-2.64	0.0600
		Wild-type	0.67	0.44-1.04	0.0710
MAGEL2	219894_at	Mutated	1.58	0.95-2.64	0.0777
		Wild-type	0.58 ^a	0.34-0.99 ^a	0.0430 ^a

P<0.05 was considered to indicate a statistically significant difference. ^aHigh mRNA expression levels associated with improved RFS; ^bhigh mRNA expression levels associated with worse RFS. Total patients assigned a TP53 status, n=595; patients with TP53-mutated breast cancer, n=232; patients with wild-type TP53 breast cancer, n=363. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen; RFS, relapse-free survival.

(HR, 0.62; 95% CI, 0.39-0.99; P=0.0433) in the mesenchymal subtype; MAGEA8 (HR, 0.41; 95% CI, 0.18-0.93; P=0.0280), MAGEC3 (HR, 0.32; 95% CI, 0.12-0.85; P=0.0159), MAGEE2 (HR, 0.34; 95% CI, 0.12-0.97; P=0.0345), MAGEF1 (HR, 0.41; 95% CI, 0.18-0.94; P=0.0292) in the mesenchymal stem-like subtype; and MAGEA5 (HR, 0.62; 95% CI, 0.41-0.93; P=0.0195), MAGEB4 (HR, 0.64; 95% CI, 0.41-1.00; P=0.0471), MAGEF1 (HR, 0.61; 95% CI, 0.41-0.91; P=0.0158) and MAGEL2 (HR, 0.61; 95% CI, 0.41-0.93; P=0.0188) in the luminal androgen receptor breast cancer subtype were significantly associated with improved RFS. However, high mRNA expression levels of MAGEH1 (HR, 1.87; 95% CI, 1.16-3.02; P=0.0090) in the basal-like 1 subtype; MAGED3 (HR, 2.93; 95% CI, 1.34-6.39; P=0.0047) in the basal-like 2 subtype; MAGEA5 (HR, 1.81; 95% CI, 1.17-2.79; P=0.0066) in the mesenchymal subtype; and MAGEH1 (HR, 1.72; 95% CI, 1.15-2.59; P=0.0079) in the luminal androgen receptor breast

cancer subtype were significantly associated with worse RFS. High mRNA expression levels of MAGED2 (HR, 1.68; 95% CI, 1.02-2.77; P=0.0386), MAGED4 (HR, 1.61; 95% CI, 1.00-2.59; P=0.0494) in the basal-like 1 subtype; MAGEB4 (HR, 2.74; 95% CI, 1.22-6.14; P=0.0106) and MAGEH1 (HR, 2.17; 95% CI, 1.06-4.40; P=0.0288) in the basal-like 2 subtype; MAGEB18 (HR, 2.39; 95% CI, 1.03-5.51; P=0.0353) and MAGEH1 (HR, 1.89; 95% CI, 1.05-3.42; P=0.0314) in the immunomodulatory subtype; MAGED3 (HR, 1.59; 95% CI, 1.04-2.43; P=0.0317), MAGEE1 (HR, 1.82; 95% CI, 1.06-3.15; P=0.0284) and MAGEH1 (HR, 1.56; 95% CI, 1.01-2.42; P=0.0421) in the mesenchymal subtype; MAGED4 (HR, 3.16; 95% CI, 0.94-10.56; P=0.0488) in the mesenchymal stem-like subtype; and MAGEB18 (HR, 2.04; 95% CI, 1.11-3.77; P=0.0211) and MAGED4 (HR, 1.59; 95% CI, 1.05-2.40; P=0.0267) in the luminal androgen receptor breast cancer subtype were significantly associated with worse RFS.

Table IV. Association between the MAGE family members and different Pietenpol subtypes of patients with breast cancer.

MAGE family member	Affymetrix ID	Pietenpol subtype	HR	95% CI	P-value
MAGEA5	214642_at	Basal-like 1	0.60 ^a	0.37-0.96 ^a	0.0327 ^a
		Basal-like 2	1.71	0.84-3.46	0.1324
		Immunomodulatory	1.48	0.73-2.99	0.2723
		Mesenchymal	1.81 ^b	1.17-2.79 ^b	0.0066 ^b
		Mesenchymal stem-like	2.62	0.78-8.76	0.1041
		Luminal androgen receptor	0.62 ^a	0.41-0.93 ^a	0.0195 ^a
MAGEA8	210274_at	Basal-like 1	0.50 ^a	0.31-0.83 ^a	0.0059 ^a
		Basal-like 2	1.51	0.75-3.06	0.2499
		Immunomodulatory	1.36	0.71-2.61	0.3555
		Mesenchymal	0.60 ^a	0.38-0.95 ^a	0.0268 ^a
		Mesenchymal stem-like	0.41 ^a	0.18-0.93 ^a	0.0280 ^a
		Luminal androgen receptor	0.52 ^a	0.31-0.85 ^a	0.0076 ^a
MAGEB4	207580_at	Basal-like 1	0.60	0.36-1.02	0.0550
		Basal-like 2	2.74 ^b	1.22-6.14 ^b	0.0106 ^b
		Immunomodulatory	0.66	0.36-1.20	0.1708
		Mesenchymal	0.82	0.5-1.33	0.4204
		Mesenchymal stem-like	0.40	0.14-1.16	0.0794
		Luminal androgen receptor	0.64 ^a	0.41-1.00 ^a	0.0471 ^a
MAGEB6	1552858_at	Basal-like 1	0.64	0.31-1.33	0.2293
		Basal-like 2	0.43 ^a	0.19-0.97 ^a	0.0356 ^a
		Immunomodulatory	0.41 ^a	0.17-0.96 ^a	0.0333 ^a
		Mesenchymal	0.47 ^a	0.24-0.89 ^a	0.0181 ^a
		Mesenchymal stem-like	0.54	0.17-1.72	0.2907
		Luminal androgen receptor	0.58	0.33-1.02	0.0546
MAGEB18	1552913_at	Basal-like 1	1.75	0.90-3.40	0.0922
		Basal-like 2	0.51	0.22-1.18	0.1092
		Immunomodulatory	2.39 ^b	1.03-5.51 ^b	0.0353 ^b
		Mesenchymal	1.70	0.98-2.93	0.0543
		Mesenchymal stem-like	0.19 ^a	0.05-0.66 ^a	0.0039 ^a
		Luminal androgen receptor	2.04 ^b	1.11-3.77 ^b	0.0211 ^b
MAGEC3	216592_at	Basal-like 1	0.63	0.35-1.14	0.1255
		Basal-like 2	0.55	0.27-1.12	0.0933
		Immunomodulatory	0.69	0.35-1.37	0.2890
		Mesenchymal	0.65	0.43-1.00	0.0505
		Mesenchymal stem-like	0.32 ^a	0.12-0.85 ^a	0.0159 ^a
		Luminal androgen receptor	0.73	0.47-1.12	0.1508
MAGED2	213627_at	Basal-like 1	1.68 ^b	1.02-2.77 ^b	0.0386 ^b
		Basal-like 2	0.46 ^a	0.23-0.95 ^a	0.0308 ^a
		Immunomodulatory	1.34	0.72-2.49	0.3553
		Mesenchymal	1.43	0.83-2.46	0.1993
		Mesenchymal stem-like	0.60	0.27-1.32	0.2002
		Luminal androgen receptor	1.32	0.86-2.02	0.2000
MAGED3	205028_at	Basal-like 1	0.74	0.43-1.25	0.2584
		Basal-like 2	2.93 ^b	1.34-6.39 ^b	0.0047 ^b
		Immunomodulatory	1.46	0.80-2.65	0.2138
		Mesenchymal	1.59 ^b	1.04-2.43 ^b	0.0317 ^b
		Mesenchymal stem-like	2.06	0.92-4.63	0.0729
		Luminal androgen receptor	0.70	0.47-1.05	0.0839
MAGED4	221261_x_at	Basal-like 1	1.61 ^b	1.00-2.59 ^b	0.0494 ^b
		Basal-like 2	0.56	0.25-1.26	0.1558
		Immunomodulatory	0.64	0.34-1.18	0.1502
		Mesenchymal	0.80	0.51-1.26	0.3402

Table IV. Continued.

MAGE family member	Affymetrix ID	Pietenpol subtype	HR	95% CI	P-value
MAGEE1	1556047_s_at	Mesenchymal stem-like	3.16 ^b	0.94-10.56 ^b	0.0488 ^b
		Luminal androgen receptor	1.59 ^b	1.05-2.40 ^b	0.0267 ^b
		Basal-like 1	1.74	0.90-3.37	0.0980
		Basal-like 2	0.25 ^a	0.07-0.85 ^a	0.0160 ^a
		Immunomodulatory	0.41	0.12-1.37	0.1343
		Mesenchymal	1.82 ^b	1.06-3.15 ^b	0.0284 ^b
		Mesenchymal stem-like	0.41	0.15-1.13	0.0757
MAGEE2	1553254_at	Luminal androgen receptor	0.73	0.43-1.26	0.2576
		Basal-like 1	0.58	0.27-1.26	0.1636
		Basal-like 2	0.60	0.25-1.43	0.2440
		Immunomodulatory	1.91	0.82-4.41	0.1257
		Mesenchymal	0.72	0.39-1.30	0.2718
		Mesenchymal stem-like	0.34 ^a	0.12-0.97 ^a	0.0345 ^a
		Luminal androgen receptor	1.59	0.90-2.80	0.1067
MAGEF1	218176_at	Basal-like 1	0.75	0.46-1.23	0.2538
		Basal-like 2	0.33 ^a	0.14-0.81 ^a	0.0110 ^a
		Immunomodulatory	0.57	0.32-1.04	0.0623
		Mesenchymal	1.67	0.98-2.84	0.0573
		Mesenchymal stem-like	0.41 ^a	0.18-0.94 ^a	0.0292 ^a
		Luminal androgen receptor	0.61 ^a	0.41-0.91 ^a	0.0158 ^a
		Basal-like 1	1.87 ^b	1.16-3.02 ^b	0.0090 ^b
MAGEH1	218573_at	Basal-like 2	2.17 ^b	1.06-4.40 ^b	0.0288 ^b
		Immunomodulatory	1.89 ^b	1.05-3.42 ^b	0.0314 ^b
		Mesenchymal	1.56 ^b	1.01-2.42 ^b	0.0421 ^b
		Mesenchymal stem-like	0.56	0.23-1.36	0.1943
		Luminal androgen receptor	1.72 ^b	1.15-2.59 ^b	0.0079 ^b
		Basal-like 1	1.55	0.96-2.49	0.0726
		Basal-like 2	0.55	0.25-1.20	0.1258
MAGEL2	219894_at	Immunomodulatory	1.63	0.82-3.25	0.1574
		Mesenchymal	0.62 ^a	0.39-0.99 ^a	0.0433 ^a
		Mesenchymal stem-like	1.50	0.67-3.33	0.3206
		Luminal androgen receptor	0.61 ^a	0.41-0.93 ^a	0.0188 ^a

P<0.05 was considered to indicate a statistically significant difference. ^aHigh mRNA expression levels associated with improved RFS; ^bhigh mRNA expression levels associated with worse RFS. Total patients assigned a Pietenpol subtype (31), n=1,246; patients with the basal-like 1 subtype, n=239; patients with the basal-like 2 subtype, n=97; patients with the immunomodulatory subtype, n=290; patients with the mesenchymal subtype, n=229; patients with the mesenchymal stem-like subtype, n=115; patients with the luminal androgen receptor subtype, n=276. CI, confidence interval; HR, hazard ratio; MAGE, melanoma-associated antigen.

Discussion

Breast cancer, which is one of the most common malignant tumors, was the second leading cause of cancer-associated mortality among women worldwide in the year 2017 (1,2). MAGE gene family members have been demonstrated to be expressed in male germ line and placental cells, as well as in a number of different tumor types, including melanoma, brain, lung, prostate and breast cancer (31,32). The aberrant expression levels of the MAGE family members have been demonstrated to be associated with progressive disease; however, the mechanisms underlying how individual MAGE family members contribute to disease occurrence are largely

unknown (33). In addition, to the best of our knowledge, many of these genes have not been reported in breast cancer.

In the present study, high mRNA expression levels of MAGEA5 were significantly associated with improved prognosis in luminal and basal-like breast cancer subtypes, and significantly associated with worse RFS in lymph node-positive breast cancer. In addition, high mRNA expression levels of MAGEA8 were significantly associated with improved prognosis in luminal and basal-like breast cancer subtypes, as well as HER2⁺ breast cancer. Previously, there have been few reports regarding the genes MAGEA5 and MAGEA8 in breast cancer, despite other members of the MAGEA family being investigated in this disease. Raghavendra *et al* (34) revealed that MAGEA1

is frequently expressed in triple-negative breast cancer, and Park *et al* (35) demonstrated that MAGEA2 promotes the progression of breast cancer by regulating the Akt and Erk1/2 pathways. Taylor *et al* (36) suggested that a vaccine that targets MAGEA10 may be of potential use in $\leq 70\%$ of breast cancers. Abd-Elsalam and Ismaeil (37) reported that measuring the expression levels of the gene MAGEA1-A6 and MAGEA12 at the same time may aid in monitoring the effectiveness of breast cancer therapy. Through a comprehensive analysis, MAGEA5 and MAGEA8 were predicted to serve a protective role in the occurrence and development of breast cancer in the present study.

The administration of a MAGEB vaccination to elderly mice (20 months) leads to the absence of CD8 T-cell responses and reduced protection against metastatic breast cancer (38). In the present study, high mRNA expression levels of MAGEB4 and MAGEB6 were significantly associated with improved RFS in all breast cancer subtypes; high MAGEB6 expression was significantly associated with improved RFS in lymph node-negative, tumor grades I and III, but was also associated with worse RFS in TP53 wild-type breast cancer. High mRNA expression levels of MAGEB4 were significantly associated with improved RFS in TP53-mutated breast cancer, but also with worse RFS in grade I breast cancer. MAGEB18 was moderately associated with worse RFS in all breast cancer, and in immunomodulatory and luminal androgen receptor breast cancer subtypes. Previous studies have demonstrated that MAGEB4 may be a potential biomarker in patients with transitional cell carcinoma (39), and that it is specifically expressed during germ cell differentiation (40). The mRNA-positivity expression of MAGEB6 is associated with a poor prognosis in patients with head and neck squamous cell carcinoma (41), and the mouse MAGEB18 gene encodes a ubiquitously expressed type I MAGE protein, and regulates cell proliferation and apoptosis in melanoma B16-F0 cells (42). Overall, to the best of our knowledge, there are currently no published studies that demonstrate the function of the MAGE family members in breast cancer, and only a small number of studies that indicate their association with other diseases. Following a detailed database analysis, MAGEB18 was predicted to have a damaging effect on the occurrence and development of breast cancer in the present study. Despite the contrasting prognostic effects of MAGEB4 and MAGEB6 in the different types of breast cancer, it could be suggested that these two molecules are more likely to serve roles as tumor suppressor genes, according to the results from the present study. Further investigation is required to verify this suggestion.

MAGEC was also analyzed in the present study. It was revealed that high mRNA expression levels of MAGEC3 were significantly associated with improved RFS in luminal, basal, HER2⁺, tumor grade II and mesenchymal stem-like breast cancer subtypes. Eng *et al* (43) indicated that MAGEC3 may be associated with earlier onset of ovarian cancer. Bao *et al* (44) used a single-cell sample of >100 pairs of primary breast cancer and corresponding metastatic lymph node samples to perform whole exome and deep-target sequencing analyses, and revealed that MAGEC3 is associated with lymph node metastasis in patients with breast cancer. In the present study it was demonstrated that high mRNA expression levels of MAGEC3 were associated with worse RFS in lymph node-status (positive) breast cancer, but were also associated with improved RFS in lymph node-status (negative) breast

cancer; however, these results were not statistically significant. These results provided further support for the hypothesis that MAGEC3 may promote cell metastasis in breast cancer, particularly lymph node metastasis.

High mRNA expression levels of MAGED2 and MAGED3 were significantly associated with improved RFS in all breast cancer. High mRNA expression levels of MAGED2 were significantly associated with improved RFS in lymph node-positive and -negative breast cancer, as well as in the basal-like 2 breast cancer subtype; in contrast, high mRNA expression levels of MAGED2 were associated with worse RFS in HER2⁺, all basal-like, TP53-mutated, tumor grade III and basal-like 1 breast cancer subtype; high mRNA expression levels of MAGED3 were significantly associated with improved RFS in luminal, lymph node-positive and TP53-mutated breast cancer, but also with worse RFS in basal-like 2 subtype, mesenchymal subtype and tumor grade III breast cancer. High mRNA expression levels of MAGED4 were significantly associated with worse RFS in lymph node-positive and -negative, TP53 wild-type, basal-like 1, mesenchymal stem-like, luminal androgen receptor breast cancer, and all breast cancer. A previous study revealed that MAGED2 is able to control cell cycle progression and modulate the DNA damage response (45), and that increased expression of MAGED2 is associated with nodal and hematogenous metastasis and is an independent prognostic factor for gastric cancer (26,46). Zhang *et al* (47) reported that MAGED4 is frequently and highly expressed in glioma, and is partly regulated by DNA methylation. Ma *et al* (48) reported that MAGED4 may be used as a specific antigen for non-small cell lung cancer to influence the improvement of diagnosis, prognosis and immunological therapy outcomes in patients with lung cancer. According to these data, it was predicted that MAGED4 may be a cancer-promoting gene in breast cancer; however, MAGED2 and MAGED3 may have different effects depending on the type of breast cancer.

High mRNA expression levels of MAGEE1 were significantly associated with improved RFS in grade I and basal-like 2 breast cancer, but also with worse RFS in grade III and mesenchymal breast cancer; high mRNA expression levels of MAGEE2 were significantly associated with improved RFS in basal, lymph node-negative and mesenchymal stem-like breast cancer, but also with worse RFS in TP53 wild-type breast cancer. MAGEE2 expression has been reported to be associated with poor OS in The Cancer Genome Atlas human breast cancer cohort (n=1,082) (49). In general, these findings indicated that MAGEE2 was closely associated with the occurrence and development of breast cancer, particularly in TP53 wild-type breast cancer. However, whether MAGEE2 can be used as a prognostic factor requires further investigation.

High mRNA expression levels of MAGEF1 were significantly associated with improved RFS in basal, lymph node-positive, grade II, basal-like 2, mesenchymal stem-like and luminal androgen receptor breast cancer, but also with worse RFS in lymph node-negative, TP53-mutated and TP53 wild-type breast cancer. Stone *et al* (50) demonstrated that MAGEF1 is ubiquitously expressed in normal tissues, as well as in melanoma, leukemia, ovarian and cervical tumor tissues and cell lines. It is possible, therefore, that the mechanism underlying MAGEF1 in these different types of breast cancer varies, but whether MAGEF1 can be used as a prognostic factor in TP53-mutated or wild-type patients requires further investigation.

Finally, high mRNA expression levels of MAGEH1 were significantly associated with worse RFS in luminal B, HER2⁺, basal, basal-like 1 and luminal androgen receptor breast cancer subtypes, but also with improved RFS in tumor grades I and II breast cancer. High mRNA expression levels of MAGEL2 were significantly associated with improved RFS in luminal A breast cancer subtypes, but also with worse RFS in tumor grade III breast cancer. Wang *et al* (51) demonstrated that MAGEH1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosis, whereas Ojima *et al* (52) revealed that negative expression (anti-MAGEH1) of the MAGEH1 protein serves as a potential predictive marker for the effectiveness of gemcitabine therapy in biliary tract carcinoma. These findings, while preliminary, suggested that MAGEH1 and MAGEL2 have effects in breast cancer patients with different pathological grades.

Despite obtaining a number of useful insights in the present study, there were some limitations. Firstly, the roles that the selected members of the MAGE family serve in breast cancer were demonstrated using bioinformatics analyses only. Secondly, the underlying molecular mechanisms were not identified. Thus, more in-depth investigations *in vitro* and *in vivo* are required in order to verify the conclusions drawn within the present study.

In summary, the prognostic value of the mRNA expression levels of 29 members of the MAGE family were analyzed in patients with breast cancer using the Kaplan-Meier plotter database. Through searching PubMed and other database, among these 29 members, 14 members were significantly associated with the prognosis of patients with breast cancer. Further investigation regarding the prognostic values of the MAGE family members in breast cancer with different clinical features suggested that MAGEA5, MAGEA8, MAGEB4 and MAGEB6 may have protective roles in the occurrence and development of breast cancer, whereas MAGEB18 and MAGED4 may possess carcinogenic effects. MAGED2, MAGED3 and MAGEF1 incur different effects depending on the type of breast cancer. It is worth noting that MAGEC3 may promote cell metastasis in breast cancer, particularly lymph node metastasis. Whether MAGEE2, MAGEH1 and MAGEL2 may be used as prognostic factors in TP53 wild-type breast cancer, as well as in the different pathological grades of breast cancer requires further study.

The present study provided novel insights regarding the contribution of the MAGE family members to breast cancer progression and may aid in the discovery of MAGE-target inhibitors for treating breast cancer.

Acknowledgements

Not applicable.

Funding

The present study was funded by Beijing Dongcheng District Excellent Talents Training Project (grant no. 2014080536381G064).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

BJ and YW conceived and designed the study. JW and YYW managed and maintained research data for initial and future use, and applied statistical, mathematical, computational, and other techniques to analyze or synthesize research data. BJ, XZ and YY prepared figures and tables, interpreted the data and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

- Mansoori B, Mohammadi A, Ghasabi M, Shirjang S, Dehghan R, Montazeri V, Holmskov U, Kazemi T, Duijff P, Gjerstorff M and Baradaran B: miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression. *J Cell Physiol* 234: 9816-9825, 2019.
- Cheng CW, Yu JC, Hsieh YH, Liao WL, Shieh JC, Yao CC, Lee HJ, Chen PM, Wu PE and Shen CY: Increased cellular levels of MicroRNA-9 and MicroRNA-221 correlate with cancer stemness and predict poor outcome in human breast cancer. *Cell Physiol Biochem* 48: 2205-2218, 2018.
- Zhao L, Zhao Y, He Y, Li Q and Mao Y: The functional pathway analysis and clinical significance of miR-20a and its related lncRNAs in breast cancer. *Cell Signal* 51: 152-165, 2018.
- Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. *CA Cancer J Clin* 68: 7-30, 2018.
- Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu L, Li X, Tao D, Gong J and Xie D: Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer. *J Exp Clin Cancer Res* 37: 175, 2018.
- Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ and Cho HJ: The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. *Blood* 106: 167-174, 2005.
- Sienel W, Varwerk C, Linder A, Kaiser D, Teschner M, Delire M, Stamatis G and Passlick B: Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: Results of a multi-center study. *Eur J Cardiothorac Surg* 25: 131-134, 2004.
- Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, Nguyen DM and Schrupp DS: Induction of MAGE-3 expression in lung and esophageal cancer cells. *Ann Thorac Surg* 71: 295-302, 2001.
- Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L and Fradet Y: High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. *Int J Cancer* 125: 1365-1371, 2009.
- Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Löning T, Jänicke F and Pantel K: MAGE-A gene expression pattern in primary breast cancer. *Cancer Res* 61: 6682-6687, 2001.
- Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. *Nat Rev Cancer* 5: 615-625, 2005.
- Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T and Lucas S: An overview of the MAGE gene family with the identification of all human members of the family. *Cancer Res* 61: 5544-5551, 2001.

13. Espantman KC and O'Shea CC: aMAGEing new players enter the RING to promote ubiquitylation. *Mol Cell* 39: 835-837, 2010.
14. Zhao J, Wang Y, Mu C, Xu Y and Sang J: MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells. *Oncogene* 36: 5023-5034, 2017.
15. Joosse SA, Müller V, Steinbach B, Pantel K and Schwarzenbach H: Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases. *Br J Cancer* 111: 909-917, 2014.
16. Ayyoub M, Scarlata CM, Hamai A, Pignon P and Valmori D: Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival. *J Immunother* 37: 73-76, 2014.
17. Cabezon T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N, Celis JE and Moreira JM: Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. *Mol Cell Proteomics* 12: 381-394, 2013.
18. Hussein YM, Gharib AF, Etewa RL, El-Shal AS, Abdel-Ghany ME and Elsayy WH: The melanoma-associated antigen-A3, -A4 genes: relation to the risk and clinicopathological parameters in breast cancer patients. *Mol Cell Biochem* 351: 261-268, 2011.
19. Lian Y, Sang M, Ding C, Zhou X, Fan X, Xu Y, Lü W and Shan B: Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: A retrospective clinical study. *J Cancer Res Clin Oncol* 138: 519-527, 2012.
20. Xu X, Tang X, Lu M, Tang Q, Zhang H, Zhu H, Xu N, Zhang D, Xiong L, Mao Y and Zhu J: Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer. *Exp Mol Pathol* 97: 579-584, 2014.
21. Hou SY, Sang MX, Geng CZ, Liu WH, Lü WH, Xu YY and Shan BE: Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism. *Arch Med Res* 45: 44-51, 2014.
22. Badovinac Crnjevic T, Spagnoli G, Juretić A, Jakić-Razumović J, Podolski P and Šarić N: High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. *Med Oncol* 29: 1586-1891, 2012.
23. Xia LP, Xu M, Chen Y and Shao WW: Expression of MAGE-A11 in breast cancer tissues and its effects on the proliferation of breast cancer cells. *Mol Med Rep* 7: 254-258, 2013.
24. Sypniewska RK, Hoflack L, Tarango M, Gauntt S, Leal BZ, Reddick RL and Gravekamp C: Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy. *Breast Cancer Res Treat* 91: 19-28, 2005.
25. Sypniewska RK, Hoflack L, Bearss DJ and Gravekamp C: Potential mouse tumor model for pre-clinical testing of mage-specific breast cancer vaccines. *Breast Cancer Res Treat* 74: 221-233, 2002.
26. Hou S, Sang M, Zhao L, Hou R and Shan B: The expression of MAGE-C1 and MAGE-C2 in breast cancer and their clinical significance. *Am J Surg* 211: 142-151, 2016.
27. Du Q, Zhang Y, Tian XX, Li Y and Fang WG: MAGE-D1 inhibits proliferation, migration and invasion of human breast cancer cells. *Oncol Rep* 22: 659-665, 2009.
28. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. *Breast Cancer Res Treat* 123: 725-731, 2010.
29. Bertero L, Massa F, Metovic J, Zanetti R, Castellano I, Ricardi U, Papotti M and Cassoni P: Eighth Edition of the UICC Classification of Malignant Tumours: An overview of the changes in the pathological TNM classification criteria-What has changed and why? *Virchows Arch* 472: 519-531, 2018.
30. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. *J Clin Oncol* 24: 5652-5657, 2006.
31. Campagnolo C, Meyers KJ, Ryan T, Atkinson RC, Chen YT, Scanlan MJ, Ritter G, Old LJ and Batt CA: Real-Time, label-free monitoring of tumor antigen and serum antibody interactions. *J Biochem Biophys Methods* 61: 283-298, 2004.
32. Krishnadas DK, Bai F and Lucas KG: Cancer testis antigen and immunotherapy. *Immunotargets Ther* 2: 11-19, 2013.
33. Weon JL and Potts PR: The MAGE protein family and cancer. *Curr Opin Cell Biol* 37: 1-8, 2015.
34. Raghavendra A, Kalita-de Croft P, Vargas AC, Smart CE, Simpson PT, Saunus JM and Lakhani SR: Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers. *Histopathology* 73: 68-80, 2018.
35. Park S, Sung Y, Jeong J, Choi M, Lee J, Kwon W, Jang S, Park SJ, Kim HS, Lee MH, *et al*: hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways. *Oncotarget* 8: 37115-37127, 2017.
36. Taylor M, Bolton LM, Johnson P, Elliott T and Murray N: Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. *Breast Cancer Res* 9: R46, 2007.
37. Abd-Elsalam EA and Ismaeil NA: Melanoma-associated antigen genes: A new trend to predict the prognosis of breast cancer patients. *Med Oncol* 31: 285, 2014.
38. Castro F, Leal B, Denny A, Bahar R, Lampkin S, Reddick R, Lu S and Gravekamp C: Vaccination with Mage-b DNA induces CD8 T-cell responses at young but not old age in mice with metastatic breast cancer. *Br J Cancer* 101: 1329-1337, 2009.
39. Afsharipad N, Nowroozi MR, Ayati M, Saffari M, Nemati S, Mohebbi E, Nekooheh L, Zendehehdel K and Modarressi MH: ODF4, MAGEA3, and MAGEB4: Potential biomarkers in patients with transitional cell carcinoma. *Iran Biomed J* 22: 160-170, 2018.
40. Osterlund C, Töhönen V, Forslund KO and Nordqvist K: Mage-b4, a novel melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation. *Cancer Res* 60: 1054-1061, 2000.
41. Zamuner FT, Karia BT, de Oliveira CZ, Santos CR, Carvalho AL and Vettore AL: A comprehensive expression analysis of cancer testis antigens in head and neck squamous cell carcinoma reveals MAGEA3/6 as a marker for recurrence. *Mol Cancer Ther* 14: 828-834, 2015.
42. Lin Y, Wen T, Meng X, Wu Z, Zhao L, Wang P, Hong Z and Yin Z: The mouse Mageb18 gene encodes a ubiquitously expressed type I MAGE protein and regulates cell proliferation and apoptosis in melanoma B16-F0 cells. *Biochem J* 443: 779-788, 2012.
43. Eng KH, Szender JB, Etter JL, Kaur J, Pobleto S, Huang RY, Zhu Q, Grzesik KA, Battaglia S, Cannioto R, *et al*: Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. *PLoS Genet* 14: e1007194, 2018.
44. Bao L, Qian Z, Lyng MB, Wang L, Yu Y, Wang T, Zhang X, Yang H, Brünner N, Wang J and Ditzel HJ: Coexisting genomic aberrations associated with lymph node metastasis in breast cancer. *J Clin Invest* 128: 2310-2324, 2018.
45. Kömhoff M and Laghmani K: MAGED2: A novel form of antenatal Bartter's syndrome. *Curr Opin Nephrol Hypertens* 27: 323-328, 2018.
46. Hashimoto R, Kanda M, Takami H, Shimizu D, Oya H, Hibino S, Okamura Y, Yamada S, Fujii T, Nakayama G, *et al*: Aberrant expression of melanoma-associated antigen-D2 serves as a prognostic indicator of hepatocellular carcinoma outcome following curative hepatectomy. *Oncol Lett* 9: 1201-1206, 2015.
47. Zhang QM, Shen N, Xie S, Bi SQ, Luo B, Lin YD, Fu J, Zhou SF, Luo GR, Xie XX and Xiao SW: MAGED4 expression in glioma and upregulation in glioma cell lines with 5-aza-2'-deoxycytidine treatment. *Asian Pac J Cancer Prev* 15: 3495-3501, 2014.
48. Ma QY, Pang LW, Chen ZM, Zhu YJ, Chen G and Chen J: The significance of MAGED4 expression in non-small cell lung cancer as analyzed by real-time fluorescence quantitative PCR. *Oncol Lett* 4: 733-738, 2012.
49. Leung YK, Govindarajah V, Cheong A, Veevers J, Song D, Gear R, Zhu X, Ying J, Kendler A, Medvedovic M, *et al*: Gestational high-fat diet and bisphenol A exposure heightens mammary cancer risk. *Endocr Relat Cancer* 24: 365-378, 2017.
50. Stone B, Schummer M, Paley PJ, Crawford M, Ford M, Urban N and Nelson BH: MAGE-F1, a novel ubiquitously expressed member of the MAGE superfamily. *Gene* 267: 173-182, 2001.
51. Wang PC, Hu ZQ, Zhou SL, Zhan H, Zhou ZJ, Luo CB and Huang XW: Downregulation of MAGE family member H1 enhances hepatocellular carcinoma progression and serves as a biomarker for patient prognosis. *Future Oncol* 14: 1177-1186, 2018.
52. Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, *et al*: Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. *Cancer Sci* 101: 882-888, 2010.

